Impact of structural biology and the protein data bank on us fda new drug approvals of low molecular weight antineoplastic agents 2019–2023 is a dataset published in Oncogene (2024). On theSindex it has a DataRank of 0.398, placing it in the top 45.9% of the data-sharing corpus. It has been cited 9 times, with 7 citing works in its 1-hop citation network.
Ranks in the top 46% for downstream scientific impact
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.345
From this paper's citation signal
Citation Network Contribution
0.0526
From 3 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 7 citers.
National Science Foundation
Grant: DBI-1832184
U.S. Department of Energy
Grant: DE-SC0019749
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Grant: R01GM133198
National Institutes of Health
Grant: 5R01GM133198-02
PDB MANAGEMENT BY THE RESEARCH COLLABORATORY FOR STRUCTURAL BIOINFORMATICS
National Institutes of Health
Grant: 1F31DE019749-01A1
Dysregulation of microRNAs in HPV-Positive Oropharyngeal Cancers
National Science Foundation
Grant: 1832184
PDB Management by The Research Collaboratory for Structural Bioinformatics
FWCI
1.44
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals